The person who prescribes your contraception has given you this sheet to give you a bit more information about the recommendations coming from a recent Europe-wide review of the safety of combined hormonal contraceptives, in particular the risk of blood clots.

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations

Recent changes made to Yacella.

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations

Combined Hormonal Contraceptives - checklist for prescribers

Combined hormonal contraceptives: Q&As about the important information for women.

Important Information for women about risk of blood clots with combined hormonal contraceptives.

The provision of this card to patients is required by the terms of the Marketing Authorisation. Please ensure that you carry this card with you at all times and that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with ipilimumab. This card was updated in September 2022 (administrative updates only). Changes to the card include the addition of the Northern Ireland emc url.

The provision of this Patient Information Guide to patients is required by the terms of the Marketing Authorisation. Please ensure that you are familiar with this material as it contains important safety information that you need to be aware of before, during and after treatment with ipilimumab. This Patient Information Guide was updated in September 2022 (administrative updates only). Changes to the material include removal of the Yervoy Patient Digital Risk Minimisation Material Platform url and addition of the Northern Ireland emc url.

Guide to handling and method of administration: To minimize the potential risk of decrease in viability of the product loss of efficacy due to inappropriate preparation of the Yescarta infusion.

Healthcare provider (HCP) educational material - To inform HCPs on how to monitor and manage symptoms associated with CRS and serious neurologic adverse reactions, and provide guidance on reporting these serious adverse reactions associated with Yescarta.

Patient Alert Card - To inform patients of the risks of CRS and serious neurologic adverse reactions, associated with Yescarta.

This card contains selected important safety information that you need to know before and during the teratment with Yuflyma

This card contains selected important safety information that you need to know before and during your child’s treatment with Yuflyma